AstraZeneca products

Cardiovascular, Renal & Metabolism

Nephropathy

Mechanism: Podocyte health; Area under investigation: nephropathy; Date commenced phase: Q1 2020; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule; Status change.

NASH

Mechanism: NASH resolution; Area under investigation: NASH; Date commenced phase: Q4 2019; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule; Status change.

Cardiovascular Disease

Mechanism: CD39L3. Area under investigation: cardiovascular disease. Date commenced phase: Q4 2020. Estimated Filing Acceptance: Country:US, EU, Japan, China, Additional information: Molecule size: Small molecule. Status change: